Telix Pharmaceuticals Limited (ASX:TLX) CEO, Dr Christian Behrenbruch discusses the company’s development pipeline and the benefit of diagnostic and therapeutic products to deliver correct doses.
- Founded in 2015 by experienced nuclear medicine executives
- Develops diagnostic and therapeutic radiopharmaceuticals
- Specialises in metastatic prostate cancer, renal cell cancer, brain cancer
- Early revenue generation from prostate cancer imaging product
- Prostate cancer radionuclide therapy is $2b opportunity
- Renal cancer patients are often mis-staged, a niche $250m opportunity
- The treatment of GBM is a $300m market opportunity
For more, watch CEO Dr Christian Behrenbruch present at FNN's Investor Event.